Skip to main content
Check our  holiday shipping & business status  ●  Meet us next:   ISSCR International Symposium (Boston) – 11-12 December 2025 Phacilitate Advanced Therapies Week – 9-12 February 2026

    Clinical Stem Cell Services

     iPSC-Derived Exosome Production Service

    REPROCELL offers iPSC-derived exosome production service at our GMP-compliant manufacturing facility in Japan for clients seeking high-quality vesicles for preclinical research. We also provide ready-to-use, highly purified and concentrated exosomes produced from our StemRNA Clinical iPSC Clones.

    Japan GMP Lab

    iPSC-derived exosomes are emerging as a highly scalable and customizable platform for next-generation extracellular vesicle therapies. iPSCs offer an ethically straightforward, readily sourced starting material that supports consistent large-scale manufacturing, advanced cargo engineering, and precise surface customization. 

    Recent studies show that iPSC-derived exosomes deliver strong regenerative and anti-senescence effects across multiple tissues, including skin, eye, vascular, and musculoskeletal systems, often outperforming MSC-derived exosomes (Wang et al., 2020). With broad therapeutic potential and unmatched flexibility, iPSC-derived exosomes are rapidly becoming a leading candidate for innovative, cell-free regenerative medicine.

    Find out more about iPSC-derived Exosomes:

    Understanding iPSC-derived Exosomes

    FAQ: iPSC Exosomes - Preclinical Research Overview

    Some therapeutic areas where iPSC-derived exosomes are being investigated
    (Wang et al., 2021):

    • Cardiovascular Disease
    • Moyamoya Disease 
    • Liver Disease
    • Ischemic limb disease
    • Bone Disease (bone defects, osteonecrosis and osteonecrosis)
    • Eye Disease (Corneal epithelial defects)
    • Neurological Disease (Alzheimer’s disease, Rett syndrome, Bipolar I disorder)
    • Skin Disease (wound healing)

    iPSC-Derived Exosome Manufacturing Services for Preclinical Research

    Why Choose REPROCELL Japan GMP Manufacturing Facility?

    iPSC-derived exosome manufacturing takes place at REPROCELL’s GMP facility in Tonomachi, Japan. The center operates under Japan’s Act on the Safety of Regenerative Medicine and maintains a certified quality management system for clinical-grade cell product manufacturing. Production takes place in rigorously controlled cleanroom environments featuring monitored air quality, aseptic processing, and strict environmental oversight. With experience supporting advanced cell-based products, including StemRNA Clinical iPSC Clones and TIL (Tumor-Infiltrating Lymphocytes) for clinical research, the facility provides a reliable foundation for producing high-quality iPSC-derived exosomes for research and clinical development.

    Let’s collaborate:

    Discover how we can take your exosome and vesicle programmes from development to GMP manufacturing with Japanese quality and global regulatory readiness. Contact us via the inquiry form

    Ready-to-use iPSC-derived Exosomes

    We also offer off-the-shelf, high-purity exosomes derived from our StemRNA™ Clinical iPSC Clones. These iPSC-derived exosomes are produced at our REPROCELL Japan GMP Manufacturing Facility, and are available worldwide for preclinical and advanced research applications. These two products are ideal for studying anti-aging and collagen production. They are available in a liquid or lyophilized form.

    Please contact us for more information